Efficacy and safety in the short-to-intermediate term of advanced combination therapy with upadacitinib for refractory Crohn's disease: real-world evidence from eastern China.

Front Med (Lausanne) · 2026 · PMC12954622 · PMID 41783069

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

These epidemiological variations contribute to a divergent demographic profile of CD patients between emerging and developed nations, with a notable trend toward a younger age group in the former, a finding that aligns with the age distribution of patients enrolled in our study.

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.